Topics:

News

News

The International Myeloma Working Group recently published a series of consensus statements discussing the use of MRI in the treatment of multiple myeloma.

Adding the PARP inhibitor veliparib to cyclophosphamide did not improve response rates or progression-free survival in ovarian cancer.

A history of hormonal contraceptive use in younger women for 5 years or more was found to be associated with a possible increased risk of glioma.

Socioeconomic factors are reducing the use of combined-modality treatment for early-stage Hodgkin lymphoma, despite its association with increased survival.

Adding cetuximab to FOLFIRI resulted in improvements in survival and objective response in patients with KRAS codon exon 2 wild-type metastatic colorectal cancer.

The TKI famitinib was associated with a significant PFS improvement in metastatic colorectal cancer patients, according to the results of a phase II study.

A study of nivolumab compared with docetaxel in patients with squamous cell NSCLC was stopped early after an analysis showed superiority of the study drug.

Pages

Subscribe to News on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.